Oncology Medical News about Hodgkin lymphoma

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Efficacy of the BEACOPP regimen in refractory and relapsed Hodgkin lymphoma
Leukemia and Lymphoma, 11/04/09

Cavalieri E et al. – BEACOPP is an effective regimen for both refractory/relapsed patients with HL after first–line treatment (Group A) and for patients relapsing after a PBSCT (Group B) with a 3–year probability of overall survival, progression–free survival, and cumulative incidence of relapse of 90, 50, and 33.3% in Group A, and 61, 31, and 37.5% in Group B, respectively.

<< Previous
Molecular prognosticators of complex karyotype soft tissue...

Next >>
Minimal residual disease is a significant predictor of treatment...